The objective of the study was to determine the relative burdens of maternal and perinatal complications, for preterm and term pre-eclampsia. Findings suggest that while adverse event risks are greater with preterm (vs term) pre-eclampsia, term disease is associated with at least equivalent total numbers of maternal, and a significant proportion of perinatal, adverse events. Increased efforts should be made to decrease the incidence of term pre-eclampsia.

https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17370

References

  1. Lisonkova  S,  Bone  JN,  Muraca  GM,  et  al.  Incidence  and  risk  factors  for  severe  preeclampsia,  hemolysis,  elevated   liver  enzymes,  and  low  platelet  count  syndrome,  and  eclampsia  at  preterm  and  term  gestation:  a  population-based  study.  Am J Obstet Gynecol2021; 225(5): 538 e1- e19

  2. Wright D, Tan MY,  O'Gorman N, Syngelaki  A,  Nicolaides KH. Serum PlGF compared with PAPP-A  in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG 2022; 129(8): 1308-17.

  3. Wright D, Tan MY,  O'Gorman N, Syngelaki  A,  Nicolaides KH. Serum PlGF compared with PAPP-A  in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG 2022; 129(8): 1308-17.

Categories

Maternal/Fetal health during pregnancy  Preterm Health  

Tags

Reply

Please Sign in (or Register) to view further.